A recent large population study of 130,000 adults in the United States failed to find evidence
for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and …

Background The classical serotonergic psychedelics LSD, psilocybin, mescaline are not
known to cause brain damage and are regarded as non-addictive. Clinical studies do not …

Mental health problems are endemic across the globe, and suicide, a strong corollary of
poor mental health, is a leading cause of death. Classic psychedelic use may occasion …

The potential of psychedelic drugs in the treatment of mental health problems is increasingly
being recognized. However, relatively little thrust has been given to the suggestion that …

We estimated lifetime prevalence of psychedelic use (lysergic acid diethylamide (LSD),
psilocybin (magic mushrooms), mescaline, and peyote) by age category using data from a …

Criminal behavior exacts a large toll on society and is resistant to intervention. Some
evidence suggests classic psychedelics may inhibit criminal behavior, but the extent of these …

Rationale A broad reassessment of the potential benefits of psychedelic drugs has led to the
initiation of multiple major clinical trials in an effort to advance their status to become FDA …

In the 1950s, the Swiss pharmaceutical company Sandoz, which employed the chemist
Albert Hofmann, who discovered lysergic acid diethylamide (LSD) and the similar …

Psychologists are a vital component of mental health treatment and their perceptions of
psychedelic-assisted therapy are critical for future implementation. This cross-sectional …

Psychedelic compounds have been linked to salutary mental health outcomes in both
naturalistic and clinical settings; however, current research on psychedelics suffers from a …